脑老化与阿尔茨海默病生物标志物之间的关联
Yousaf Abughofah1, Rachael Deardorff2,3, Aaron Vosmeier2,3
1Indiana Medical Student Program for Research and Scholarship, Indiana University School of Medicine Indianapolis Indiana USA.
Alzheimer's & dementia (Amsterdam, Netherlands)
|February 28, 2025
概括
使用人工智能的大脑年龄差距估计显示了与阿尔茨海默病生物标志物的联系. 这种脑成像方法可能有助于早期诊断和治疗策略.
科学领域:
- 神经成像是一种神经成像.
- 人工智能的人工智能
- 生物标志物发现发现
背景情况:
- 大脑年龄差距估计 (BrainAGE) 利用结构性MRI扫描上的机器学习.
- 这项研究旨在将大脑年龄与阿尔茨海默病 (AD) 成像和血生物标志物联系起来.
研究的目的:
- 为了研究大脑年龄差距 (BAG) 和AD生物标志物之间的关联.
- 探索这些关联在疾病阶段之间如何不同.
主要方法:
- 从123名参与者中收集了结构性MRI,粉样和蛋白PET扫描以及血样本.
- 使用BrainAgeR软件生成大脑年龄估计.
- 部分皮尔森相关性模型评估了BAG和生物标志物之间的关系.
主要成果:
- 在BAG和粉样蛋白/粉样蛋白和血生物标志物之间发现了显著的关联.
- 这些关联根据诊断类别 (临床前与临床AD) 不同.
结论:
- 大脑年龄差异显示了作为AD病理学的生物标志物的潜力.
- 这种方法可以整合到常规脑成像中,用于早期AD检测.
相关概念视频
01:26Alzheimer's Disease: Overview
418
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
418
01:22Alzheimer's Disease: Treatment
145
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
145